Developer docs
API playgroundTry for free, no card

Search company profiles

INmuneBIO

Full company profile

uuid0002k9o

Namestring
INmuneBIO
Legal namestring
INmune Bio Inc.
Websiteurl
inmunebio.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

INmune Bio Inc. is a clinical-stage biotechnology company developing immunotherapies that reprogram the patient's innate immune system to fight cancer, neurodegenerative disease, and rare inflammatory conditions. The company operates four core platforms: the DN-TNF platform with lead asset XPro1595 (pegipanermin), a dominant-negative tumor necrosis factor inhibitor that selectively neutralizes soluble TNF to reduce neuroinflammation without compromising protective immune function; the CORDStrom MSC platform delivering pooled, allogeneic, umbilical cord-derived mesenchymal stromal cells, with lead indication Ebstrocel for Recessive Dystrophic Epidermolysis Bullosa (RDEB); the INKmune NK cell priming platform for hematologic malignancies; and INB03, a soluble TNF inhibitor targeting myeloid-derived suppressor cells in solid tumors. The company has received FDA Fast Track designation for XPro1595 and Orphan Drug plus Rare Pediatric Disease designations for CORDStrom, with FDA End-of-Phase 2 alignment secured for an integrated Phase 2b/3 registration pathway.

INmune Bio serves three primary patient segments: approximately 300 RDEB children in the UK (5,000+ in the broader EB community), early Alzheimer's disease patients with inflammatory biomarkers (a market projected to grow from $4 billion in 2025 to $40 billion by 2036 in the 7MM), and oncology patients with HER2+ breast cancer and other immunotherapy-resistant solid tumors. Phase 2 MINDFuL trial data for XPro1595 demonstrated statistically significant treatment effect on myelin (p=0.0028 full population; p=0.0098 biomarker-enriched) with no observed ARIA-E or ARIA-H brain imaging abnormalities, while MissionEB Phase III data for CORDStrom showed 26% itch reduction at six months with significant pain, skin, and quality-of-life improvements.

INmune Bio is pre-revenue with no approved products and no commercial sales. The future business model contemplates revenue from approved biopharmaceutical products distributed through specialty pharmacy channels and hospital/academic medical center dispensaries typical for rare disease and neurology biologics. The company held $24.8 million in cash as of December 31, 2025, providing runway through Q1 2027, with cumulative capital raised since the 2019 IPO exceeding $130 million across public offerings, registered direct offerings, an ATM facility, and a $15 million Silicon Valley Bank credit facility. Key manufacturing and supply partnerships include CGT Catapult for commercial-scale CORDStrom production and Anthony Nolan for umbilical cord tissue procurement.

Short descriptiontext

INmune Bio is a clinical-stage biotechnology company developing innate immune system immunotherapies for Alzheimer's disease, rare diseases like RDEB, and cancer. Pre-revenue, with multiple platforms advancing toward FDA and MHRA regulatory submissions targeted for 2026-2027.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoca Raton, United States
HQ citystring
Boca Raton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immunotherapy development, cell therapy platforms, biopharmaceutical products, Alzheimer's therapeutics, rare disease treatments
Industry2 codes
PRIMARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-Stage Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biopharmaceutical Product Revenue
TypeOne Time License
Description

Pre-revenue clinical-stage biotechnology company. Expected future revenue from sale of approved biopharmaceutical products including CORDStrom for RDEB and XPro1595 for Alzheimer's disease. No products currently approved or generating revenue.

biospace.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1CORDStrom
Description

A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell (hucMSC) platform for treating Recessive Dystrophic Epidermolysis Bullosa (RDEB) and other inflammatory diseases. Ebstrocel is the RDEB-specific formulation derived from this platform.

inmunebio.com
+3 more records
Core offering1 text field

INmune Bio is a clinical-stage biotechnology company developing first-in-class immunotherapies that reprogram the innate immune system to fight disease. The company's pipeline is anchored by two lead programs: CORDStrom (Ebstrocel), a pooled allogeneic human umbilical cord-derived mesenchymal stromal cell (hucMSC) platform targeting Recessive Dystrophic Epidermolysis Bullosa (RDEB), and XPro1595 (pegipanermin), a dominant-negative TNF (DN-TNF) inhibitor for early Alzheimer's disease. Additional programs include INKmune (NK cell priming pseudokine) and INB03 (soluble TNF inhibitor) for oncology indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 26% itch reduction at 6 months in RDEB patients treated with CORDStrom
+4 more records
Product overview1 text field

INmune Bio Inc. is a clinical-stage biotechnology company developing immunotherapies that reprogram a patient's innate immune system to fight cancer and Alzheimer's disease. The company operates two main product platforms: the DN-TNF (Dominant-Negical TNF) platform comprising XPro1595 (pegipanermin), INB03, Quellor, and LIVNate, which selectively neutralizes soluble TNF to treat inflammation-driven diseases; and the Natural Killer Cell Priming Platform featuring INKmune for cancer treatment. Additionally, the CORDStrom mesenchymal stromal cell platform is advancing toward regulatory filings for Recessive Dystrophic Epidermolysis Bullosa (RDEB). The company utilizes a precision medicine approach, matching drug mechanisms to patient biology.

Product and service4 records
1XPro1595 (pegipanermin)
CategoryBiopharmaceutical / Biologic Therapy
Description

A next-generation Dominant-Negative Tumor Necrosis Factor (DN-TNF) biologic that selectively neutralizes soluble TNF (sTNF) to eliminate neuroinflammation without compromising protective immune function. In Phase 2b/3 registrational development for early Alzheimer's disease with biomarkers of inflammation.

2CORDStrom (Ebstrocel)
CategoryCell Therapy / Regenerative Medicine
Description

A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell (hucMSC) platform engineered to address donor variability and manufacturing inconsistency. Lead indication is RDEB, a rare genetic skin disorder causing severe wounds, intractable itch, and chronic pain.

3INKmune
CategoryCell-Based Immunotherapy
Description

A natural killer (NK) cell priming platform delivered as a pharmaceutical-grade, replication-incompetent tumor cell that primes patients' resting NK cells to eliminate minimal residual disease in cancer patients, including high-risk MDS and ovarian cancer.

4INB03
CategoryBiopharmaceutical / Oncology Therapy
Description

A soluble TNF inhibitor targeting myeloid-derived suppressor cells (MDSC) to overcome resistance to immunotherapy such as anti-PD1 checkpoint inhibitors. In development for MUC4-expressing cancers and HER2-positive breast cancer.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-05
Description

INmune Bio became a founding member of ABIA, a coalition of 21-26 biotech companies developing a national innovation roadmap to sustain U.S. leadership in biotechnology. The alliance addresses declining public investment, capital market volatility, regulatory complexity, and global competition through Vision 2030 strategy focusing on manufacturing capacity, research investment, regulatory flexibility, and workforce development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-29
Description

Expanded collaboration with Anthony Nolan, a UK-based stem cell charity with 50 years of expertise, to secure umbilical cord tissue for CORDStrom MSC platform development. The restated agreement secures long-term provision of umbilical cord tissue from Anthony Nolan's procurement infrastructure to support development of off-the-shelf cellular treatments for RDEB, oncology applications, and inflammatory diseases (osteoarthritis, systemic lupus erythematosus).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-11
Description

Partnership with Cell and Gene Therapy Catapult (CGT Catapult) for commercial manufacturing of CORDStrom. Three commercial pilot-scale manufacturing runs completed at the CGT Catapult facility in the UK, each meeting predefined release criteria and confirming commercial supply readiness.

Strategic tierMinorTypeOthersAnnounced on2021-06-14
Description

$15 million credit facility with Silicon Valley Bank to fund buyout of option held by Xencor, Inc. Transaction included $15 million cash payment and $3.3 million in shares to Xencor, preventing approximately 2.1 million shares of potential future stock dilution.

Strategic tierMinorTypeOthers
Description

Mentioned as supporting organization for epidermolysis bullosa patient community. Approximately 300 children in UK affected by RDEB, part of broader EB community of at least 5,000 individuals.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Cortexyme is a clinical-stage biotech developing therapeutics targeting microbial pathogens in neurodegenerative disease, including Alzheimer's. Comparable as a small-cap clinical-stage neuroscience biotech pursuing novel mechanisms, though with a different therapeutic hypothesis.

TypeDirect peer
Description

Nkarta is a clinical-stage biotech engineering allogeneic NK cell therapies for cancer, including hematologic malignancies. Closely comparable to INKmune for NK cell-based oncology approaches, though Nkarta uses gene-engineered NK cells rather than in vivo priming.

TypeDirect peer
Description

Annovis Bio is a clinical-stage biotech developing neurodegenerative disease therapeutics targeting toxic protein aggregates and inflammation. Comparable as a small-cap biotech advancing novel mechanisms for Alzheimer's and Parkinson's, with overlapping biomarker-driven patient enrichment approaches.

TypeDirect peer
Description

Fate Therapeutics is a clinical-stage biotech developing off-the-shelf NK cell and T-cell cancer immunotherapies. Directly comparable to INmune Bio's INKmune NK cell priming platform in oncology, with similar iPSC-derived and engineered NK cell approaches for hematologic malignancies and solid tumors.

TypeDirect peer
Description

Mesoblast is a commercial-stage cell therapy company developing allogeneic mesenchymal lineage cell therapies for inflammatory and rare diseases. Highly comparable to INmune Bio's CORDStrom MSC platform, with similar manufacturing, regulatory, and commercialization dynamics in specialty biologics.

6Cassava Sciences
TypeDirect peer
Description

Cassava Sciences is a clinical-stage biotechnology company developing treatments for Alzheimer's disease, with a late-stage asset in pivotal trials. Directly comparable to INmune Bio's XPro1595 program as another small-cap, clinical-stage Alzheimer's biotech pursuing a differentiated mechanism.

7Pluristem Therapeutics
TypeEmerging player
Description

Pluristem Therapeutics is a clinical-stage regenerative medicine company developing placenta-derived allogeneic cell therapies for inflammatory and ischemic conditions. Comparable as a small-cap allogeneic cell therapy peer, though using a different cell source (placenta vs. umbilical cord) and earlier-stage pipeline.

TypeDirect peer
Description

Alector is a clinical-stage biotech developing immuno-neurology treatments for neurodegenerative diseases, including Alzheimer's, with a focus on neuroinflammation biology. Highly comparable to INmune Bio's XPro1595 program, and notably was a lead investor in INmune Bio's early financing, validating overlapping scientific conviction.

TypeEmerging player
Description

ProKidney is a clinical-stage cell therapy company developing autologous cell therapies for chronic kidney disease. Comparable to INmune Bio as another clinical-stage biotech using cell-based approaches for serious diseases with limited treatment options, though focused on renal rather than dermatologic or neurologic indications.

TypeDirect peer
Description

Lineage Cell Therapeutics is a clinical-stage cell therapy company developing allogeneic cell transplant therapies for CNS disorders, oncology, and rare diseases. Comparable to CORDStrom as another small-cap allogeneic cell therapy biotech pursuing regulatory approvals in underserved indications.

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

INmuneBIO

Clinical-Stage Biopharmaceuticalsinmunebio.com

INmune Bio is a clinical-stage biotechnology company developing innate immune system immunotherapies for Alzheimer's disease, rare diseases like RDEB, and cancer. Pre-revenue, with multiple platforms advancing toward FDA and MHRA regulatory submissions targeted for 2026-2027.

What INmuneBIO does

INmune Bio Inc. is a clinical-stage biotechnology company developing immunotherapies that reprogram the patient's innate immune system to fight cancer, neurodegenerative disease, and rare inflammatory conditions. The company operates four core platforms: the DN-TNF platform with lead asset XPro1595 (pegipanermin), a dominant-negative tumor necrosis factor inhibitor that selectively neutralizes soluble TNF to reduce neuroinflammation without compromising protective immune function; the CORDStrom MSC platform delivering pooled, allogeneic, umbilical cord-derived mesenchymal stromal cells, with lead indication Ebstrocel for Recessive Dystrophic Epidermolysis Bullosa (RDEB); the INKmune NK cell priming platform for hematologic malignancies; and INB03, a soluble TNF inhibitor targeting myeloid-derived suppressor cells in solid tumors. The company has received FDA Fast Track designation for XPro1595 and Orphan Drug plus Rare Pediatric Disease designations for CORDStrom, with FDA End-of-Phase 2 alignment secured for an integrated Phase 2b/3 registration pathway.

INmune Bio serves three primary patient segments: approximately 300 RDEB children in the UK (5,000+ in the broader EB community), early Alzheimer's disease patients with inflammatory biomarkers (a market projected to grow from $4 billion in 2025 to $40 billion by 2036 in the 7MM), and oncology patients with HER2+ breast cancer and other immunotherapy-resistant solid tumors. Phase 2 MINDFuL trial data for XPro1595 demonstrated statistically significant treatment effect on myelin (p=0.0028 full population; p=0.0098 biomarker-enriched) with no observed ARIA-E or ARIA-H brain imaging abnormalities, while MissionEB Phase III data for CORDStrom showed 26% itch reduction at six months with significant pain, skin, and quality-of-life improvements.

INmune Bio is pre-revenue with no approved products and no commercial sales. The future business model contemplates revenue from approved biopharmaceutical products distributed through specialty pharmacy channels and hospital/academic medical center dispensaries typical for rare disease and neurology biologics. The company held $24.8 million in cash as of December 31, 2025, providing runway through Q1 2027, with cumulative capital raised since the 2019 IPO exceeding $130 million across public offerings, registered direct offerings, an ATM facility, and a $15 million Silicon Valley Bank credit facility. Key manufacturing and supply partnerships include CGT Catapult for commercial-scale CORDStrom production and Anthony Nolan for umbilical cord tissue procurement.

INmuneBIO firmographics

Firmographics
Name
INmuneBIO
Legal name
INmune Bio Inc.
Website
https://inmunebio.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
INmune Bio is a clinical-stage biotechnology company developing innate immune system immunotherapies for Alzheimer's disease, rare diseases like RDEB, and cancer. Pre-revenue, with multiple platforms advancing toward FDA and MHRA regulatory submissions targeted for 2026-2027.
Ownership category
akta.pro rank

INmuneBIO industry classification

Industry
Product category
Clinical-Stage Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Immunotherapy development
  • Cell therapy platforms
  • Biopharmaceutical products
  • Alzheimer's therapeutics
  • Rare disease treatments

Where INmuneBIO is headquartered

Location

Headquarters

HQ city
Boca Raton
HQ country
United States
HQ region
North America

Offices3 records

Markets served

INmuneBIO business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Biopharmaceutical Product Revenue: Pre-revenue clinical-stage biotechnology company. Expected future revenue from sale of approved biopharmaceutical products including CORDStrom for RDEB and XPro1595 for Alzheimer's disease. No products currently approved or generating revenue.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

INmuneBIO product offering

Product offering

Core offering

INmune Bio is a clinical-stage biotechnology company developing first-in-class immunotherapies that reprogram the innate immune system to fight disease. The company's pipeline is anchored by two lead programs: CORDStrom (Ebstrocel), a pooled allogeneic human umbilical cord-derived mesenchymal stromal cell (hucMSC) platform targeting Recessive Dystrophic Epidermolysis Bullosa (RDEB), and XPro1595 (pegipanermin), a dominant-negative TNF (DN-TNF) inhibitor for early Alzheimer's disease. Additional programs include INKmune (NK cell priming pseudokine) and INB03 (soluble TNF inhibitor) for oncology indications.

Product overview

INmune Bio Inc. is a clinical-stage biotechnology company developing immunotherapies that reprogram a patient's innate immune system to fight cancer and Alzheimer's disease. The company operates two main product platforms: the DN-TNF (Dominant-Negical TNF) platform comprising XPro1595 (pegipanermin), INB03, Quellor, and LIVNate, which selectively neutralizes soluble TNF to treat inflammation-driven diseases; and the Natural Killer Cell Priming Platform featuring INKmune for cancer treatment. Additionally, the CORDStrom mesenchymal stromal cell platform is advancing toward regulatory filings for Recessive Dystrophic Epidermolysis Bullosa (RDEB). The company utilizes a precision medicine approach, matching drug mechanisms to patient biology.

Differentiator

Problem solved

Functional benefit

Brands

  • CORDStrom: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell (hucMSC) platform for treating Recessive Dystrophic Epidermolysis Bullosa (RDEB) and other inflammatory diseases. Ebstrocel is the RDEB-specific formulation derived from this platform.
  • XPro
  • INKmune
  • INB03

Products and services

  • XPro1595 (pegipanermin) A next-generation Dominant-Negative Tumor Necrosis Factor (DN-TNF) biologic that selectively neutralizes soluble TNF (sTNF) to eliminate neuroinflammation without compromising protective immune function. In Phase 2b/3 registrational development for early Alzheimer's disease with biomarkers of inflammation.
  • CORDStrom (Ebstrocel) A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell (hucMSC) platform engineered to address donor variability and manufacturing inconsistency. Lead indication is RDEB, a rare genetic skin disorder causing severe wounds, intractable itch, and chronic pain.
  • INKmune A natural killer (NK) cell priming platform delivered as a pharmaceutical-grade, replication-incompetent tumor cell that primes patients' resting NK cells to eliminate minimal residual disease in cancer patients, including high-risk MDS and ovarian cancer.
  • INB03 A soluble TNF inhibitor targeting myeloid-derived suppressor cells (MDSC) to overcome resistance to immunotherapy such as anti-PD1 checkpoint inhibitors. In development for MUC4-expressing cancers and HER2-positive breast cancer.

Quantifiable outcome

  • 26% itch reduction at 6 months in RDEB patients treated with CORDStrom
  • +4 more outcomes

Companies that use INmuneBIO

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

INmuneBIO technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

INmuneBIO partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • American Biotech Innovation Alliance (ABIA)minorStrategic or Co-development Partner · 5 May 2026INmune Bio became a founding member of ABIA, a coalition of 21-26 biotech companies developing a national innovation roadmap to sustain U.S. leadership in biotechnology. The alliance addresses declining public investment, capital market volatility, regulatory complexity, and global competition through Vision 2030 strategy focusing on manufacturing capacity, research investment, regulatory flexibility, and workforce development.
  • Anthony NolancoreStrategic or Co-development Partner · 29 April 2026Expanded collaboration with Anthony Nolan, a UK-based stem cell charity with 50 years of expertise, to secure umbilical cord tissue for CORDStrom MSC platform development. The restated agreement secures long-term provision of umbilical cord tissue from Anthony Nolan's procurement infrastructure to support development of off-the-shelf cellular treatments for RDEB, oncology applications, and inflammatory diseases (osteoarthritis, systemic lupus erythematosus).
  • CGT CatapultcoreStrategic or Co-development Partner · 11 February 2026Partnership with Cell and Gene Therapy Catapult (CGT Catapult) for commercial manufacturing of CORDStrom. Three commercial pilot-scale manufacturing runs completed at the CGT Catapult facility in the UK, each meeting predefined release criteria and confirming commercial supply readiness.
  • Xencor, Inc.minorOthers · 14 June 2021$15 million credit facility with Silicon Valley Bank to fund buyout of option held by Xencor, Inc. Transaction included $15 million cash payment and $3.3 million in shares to Xencor, preventing approximately 2.1 million shares of potential future stock dilution.
  • DEBRA UKminorOthersMentioned as supporting organization for epidermolysis bullosa patient community. Approximately 300 children in UK affected by RDEB, part of broader EB community of at least 5,000 individuals.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

INmuneBIO competitors and assessment

Company assessment

Emerging players

  • Cortexyme: Cortexyme is a clinical-stage biotech developing therapeutics targeting microbial pathogens in neurodegenerative disease, including Alzheimer's. Comparable as a small-cap clinical-stage neuroscience biotech pursuing novel mechanisms, though with a different therapeutic hypothesis.
  • Pluristem Therapeutics: Pluristem Therapeutics is a clinical-stage regenerative medicine company developing placenta-derived allogeneic cell therapies for inflammatory and ischemic conditions. Comparable as a small-cap allogeneic cell therapy peer, though using a different cell source (placenta vs. umbilical cord) and earlier-stage pipeline.
  • ProKidney: ProKidney is a clinical-stage cell therapy company developing autologous cell therapies for chronic kidney disease. Comparable to INmune Bio as another clinical-stage biotech using cell-based approaches for serious diseases with limited treatment options, though focused on renal rather than dermatologic or neurologic indications.

Direct peers

  • Nkarta: Nkarta is a clinical-stage biotech engineering allogeneic NK cell therapies for cancer, including hematologic malignancies. Closely comparable to INKmune for NK cell-based oncology approaches, though Nkarta uses gene-engineered NK cells rather than in vivo priming.
  • Annovis Bio: Annovis Bio is a clinical-stage biotech developing neurodegenerative disease therapeutics targeting toxic protein aggregates and inflammation. Comparable as a small-cap biotech advancing novel mechanisms for Alzheimer's and Parkinson's, with overlapping biomarker-driven patient enrichment approaches.
  • Fate Therapeutics: Fate Therapeutics is a clinical-stage biotech developing off-the-shelf NK cell and T-cell cancer immunotherapies. Directly comparable to INmune Bio's INKmune NK cell priming platform in oncology, with similar iPSC-derived and engineered NK cell approaches for hematologic malignancies and solid tumors.
  • Mesoblast: Mesoblast is a commercial-stage cell therapy company developing allogeneic mesenchymal lineage cell therapies for inflammatory and rare diseases. Highly comparable to INmune Bio's CORDStrom MSC platform, with similar manufacturing, regulatory, and commercialization dynamics in specialty biologics.
  • Cassava Sciences: Cassava Sciences is a clinical-stage biotechnology company developing treatments for Alzheimer's disease, with a late-stage asset in pivotal trials. Directly comparable to INmune Bio's XPro1595 program as another small-cap, clinical-stage Alzheimer's biotech pursuing a differentiated mechanism.
  • Alector: Alector is a clinical-stage biotech developing immuno-neurology treatments for neurodegenerative diseases, including Alzheimer's, with a focus on neuroinflammation biology. Highly comparable to INmune Bio's XPro1595 program, and notably was a lead investor in INmune Bio's early financing, validating overlapping scientific conviction.
  • Lineage Cell Therapeutics: Lineage Cell Therapeutics is a clinical-stage cell therapy company developing allogeneic cell transplant therapies for CNS disorders, oncology, and rare diseases. Comparable to CORDStrom as another small-cap allogeneic cell therapy biotech pursuing regulatory approvals in underserved indications.

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

INmuneBIO social profiles

Digital presence

INmuneBIO compliance and trust

Trust signal

Compliance3 records

INmuneBIO financial estimates

Financial estimate

Revenue estimate

Valuation estimate

INmuneBIO leadership team

Management profile

Number of profiles

Profiles10 records

INmuneBIO funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

INmuneBIO M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about INmuneBIO

What does INmuneBIO do?

INmune Bio is a clinical-stage biotechnology company developing first-in-class immunotherapies that reprogram the innate immune system to fight disease. The company's pipeline is anchored by two lead programs: CORDStrom (Ebstrocel), a pooled allogeneic human umbilical cord-derived mesenchymal stromal cell (hucMSC) platform targeting Recessive Dystrophic Epidermolysis Bullosa (RDEB), and XPro1595 (pegipanermin), a dominant-negative TNF (DN-TNF) inhibitor for early Alzheimer's disease. Additional programs include INKmune (NK cell priming pseudokine) and INB03 (soluble TNF inhibitor) for oncology indications.

Is INmuneBIO a public or private company?

INmuneBIO is a public company. It is classified as public and is currently operating.

When was INmuneBIO founded?

INmuneBIO was founded in 2015. It employs 11 to 50 people.

Where is INmuneBIO based?

INmuneBIO is headquartered in Boca Raton, United States, in the North America region.

How does INmuneBIO make money?

One revenue line is on record: biopharmaceutical Product Revenue.

Who are INmuneBIO's main competitors?

Emerging players on record are Cortexyme, Pluristem Therapeutics and ProKidney. Direct peers are Nkarta, Annovis Bio, Fate Therapeutics, Mesoblast, Cassava Sciences, Alector and Lineage Cell Therapeutics.

Does INmuneBIO have an API?

No public API is recorded for INmuneBIO.

What industry is INmuneBIO in?

INmuneBIO's product category is Clinical-Stage Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewFreedom Broker maintains INmune Bio at Buy, lowers price target to $2.50 from $4Freedom Broker maintained INmune Bio at Buy and lowered its price target to $2.50 from $4, a 37.5% cut. The target implies 138.1% upside from the Nov 12 close of $1.05.Quantum ZeitgeistQCi’s $1.3 billion cash unlocks growth potentialQuantum Computing Inc. reported $9.5 million in Q3 2026 revenue, surpassing its first-half total, with $1.3 billion in cash and investments. The company posted a net loss of $15.1 million, reflecting ongoing R&D and integration costs. It also entered a framework agreement with Hamad Bin Khalifa University and secured its first commercial customer with INmune Bio.Seeking AlphaINmune Bio Inc. (INMB) Q3 2026 Earnings Call Prepared Remarks TranscriptINmune Bio held its Q3 2026 earnings call on November 5, 2026, with CEO David Moss, CSO Mark Lowdell, and CFO Cory Ellspermann. The call included no question-and-answer session, and no financial results or forward-looking statements were disclosed.The Motley FoolINmune Bio (INMB) Q3 2026 Earnings Call TranscriptINmune Bio reported a Q3 2026 net loss of $4.7 million, down from $6.5 million a year earlier, with cash of $16.3 million. The company plans a UK marketing authorization application in early February 2027, targeting approval by mid-2027, and a U.S. BLA submission in mid-2027.The Motley FoolINmune Bio (INMB) Q3 2026 Earnings Call TranscriptINmune Bio reported a Q3 2026 net loss of $4.7 million, down from $6.5 million a year earlier, with cash of $16.3 million. The company plans a UK marketing authorization application in early February 2027, targeting approval by mid-2027, and a U.S. BLA submission in mid-2027.Business & FinancialInmune Bio Inc. Announces Third Quarter 2026 Results And Provides Business UpdateINmune Bio reported a Q3 2026 net loss of $4.7 million and $16.3 million in cash, with R&D expenses of $3.2 million. The company submitted its final pre-MAA for Ebstrocel to the UK MHRA on October 20, 2026, and plans a complete MAA in early 2027. It also raised $4.5 million in a stock offering and expects potential UK approval in mid-2027.FinancialContent Business PageINmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5thINmune Bio Inc. will host a conference call on November 5th, 2026 at 4:30pm EDT to report its third-quarter 2026 financial results and provide a corporate update. The company's two late-stage product platforms, CORDStrom and XPro1595, are advancing toward registrational milestones, with a UK MHRA and EU EMA MAA planned in 2026.GlobeNewswireINmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5thINmune Bio Inc. will host a conference call on November 5th, 2026, to report Q3 2026 results and provide a corporate update. The company is advancing CORDStrom and XPro1595 platforms toward registrational milestones, with a UK MHRA and EU EMA MAA planned in 2026 and a U.S. BLA submission.Business & FinancialInmune Bio, Inc. Announces Pricing Of $4.50 Million Registered Direct Offering And Concurrent Private PlacementInmune Bio announced a $4.50 million registered direct offering and concurrent private placement, with closing expected on or about October 29, 2026. Proceeds will be used for working capital and general corporate procedures. The company also outlined its late-stage product platforms CORDStrom and XPro1595.The future of tradingINmune Bio Inc <inmb.oq> expected to post a loss of 15 cents a share - Earnings PreviewINmune Bio Inc is expected to report a loss of 15 cents per share for the quarter ending September 30, 2026, with revenue unchanged. Analysts rate the stock a buy, and the median 12-month price target is $8.00, about 447.9% above the last closing price of $1.46.